Anticipated impact of novel adult-specific pneumococcal conjugate vaccine

IF 4.5 3区医学 Q2 IMMUNOLOGY

Vaccine Pub Date : 2025-04-13 DOI:10.1016/j.vaccine.2025.127080

R. Joshi, H.T. Ayele, K.D. Johnson, P. Velentgas, H. Platt, P. Saddier

{"title":"Anticipated impact of novel adult-specific pneumococcal conjugate vaccine","authors":"R. Joshi, H.T. Ayele, K.D. Johnson, P. Velentgas, H. Platt, P. Saddier","doi":"10.1016/j.vaccine.2025.127080","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The incidence of IPD in adults, while largely decreased from indirect effect of pediatric PCVs, remains high.</div></div><div><h3>Objective</h3><div>To describe differences in the expected serotype coverage and incidence of IPD by V116, a novel adult-specific PCV, and other licensed PCVs used in adults.</div></div><div><h3>Methods</h3><div>We used national IPD surveillance serotype distribution data from 7 countries (US, Canada, UK, Germany, France, Spain, and Australia). We calculated serotype coverage offered by V116 and PCV20 in adults 65+ (or 60+) years old in 2022 (2019 for UK, France). For all countries except Germany, we reported incidence/notification rates of IPD due to serotypes in V116 versus other PCVs in 2019. As an example, we estimated annual numbers of US cases potentially prevented, assuming 100 % vaccine efficacy and uptake for both vaccines.</div></div><div><h3>Results</h3><div>From 7 countries, coverage conferred by V116 in adults 65+ in 2019–2022 ranged from 66 %–88 % of IPD cases while PCV20 coverage ranged from 50 %–66 %. The incidence of IPD among adults 65+ caused by serotypes included in V116 is higher in all six countries compared to other PCVs in 2019. In US, the annual incidence of IPD (per 100,000) among 65+ was 24; the incidence caused by serotypes in V116 was 20 cases compared to 12 from PCV20 serotypes. Of the estimated total 12,800 annual IPD cases in 2019 in the US, V116 could potentially prevent ∼8200 cases compared to ∼5000 by PCV20.</div></div><div><h3>Conclusions</h3><div>Based on IPD surveillance data from key countries, serotype coverage by V116 was ∼16–33 % higher than that by PCV20 among adults 65+ years in 2022 (data for UK, France from 2019). V116 includes serotypes responsible for the majority of IPD and is expected to prevent more IPD cases than PCV20 among 65+.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"53 ","pages":"Article 127080"},"PeriodicalIF":4.5000,"publicationDate":"2025-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X25003779","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The incidence of IPD in adults, while largely decreased from indirect effect of pediatric PCVs, remains high.

Objective

To describe differences in the expected serotype coverage and incidence of IPD by V116, a novel adult-specific PCV, and other licensed PCVs used in adults.

Methods

We used national IPD surveillance serotype distribution data from 7 countries (US, Canada, UK, Germany, France, Spain, and Australia). We calculated serotype coverage offered by V116 and PCV20 in adults 65+ (or 60+) years old in 2022 (2019 for UK, France). For all countries except Germany, we reported incidence/notification rates of IPD due to serotypes in V116 versus other PCVs in 2019. As an example, we estimated annual numbers of US cases potentially prevented, assuming 100 % vaccine efficacy and uptake for both vaccines.

Results

From 7 countries, coverage conferred by V116 in adults 65+ in 2019–2022 ranged from 66 %–88 % of IPD cases while PCV20 coverage ranged from 50 %–66 %. The incidence of IPD among adults 65+ caused by serotypes included in V116 is higher in all six countries compared to other PCVs in 2019. In US, the annual incidence of IPD (per 100,000) among 65+ was 24; the incidence caused by serotypes in V116 was 20 cases compared to 12 from PCV20 serotypes. Of the estimated total 12,800 annual IPD cases in 2019 in the US, V116 could potentially prevent ∼8200 cases compared to ∼5000 by PCV20.

Conclusions

Based on IPD surveillance data from key countries, serotype coverage by V116 was ∼16–33 % higher than that by PCV20 among adults 65+ years in 2022 (data for UK, France from 2019). V116 includes serotypes responsible for the majority of IPD and is expected to prevent more IPD cases than PCV20 among 65+.

查看原文本刊更多论文

背景成人 IPD 的发病率虽然因儿科 PCV 的间接影响而大大降低，但仍然很高。目的描述新型成人特异性 PCV V116 和其他用于成人的特许 PCV 在 IPD 的预期血清型覆盖率和发病率方面的差异。我们计算了 2022 年（英国和法国为 2019 年）V116 和 PCV20 在 65 岁以上（或 60 岁以上）成人中的血清型覆盖率。对于除德国以外的所有国家，我们报告了 2019 年 V116 与其他 PCV 血清型导致的 IPD 发病率/通知率。结果在 7 个国家中，2019-2022 年 V116 疫苗对 65 岁以上成人 IPD 病例的覆盖率为 66 %-88 %，而 PCV20 的覆盖率为 50 %-66 %。与其他 PCV 相比，2019 年 V116 所含血清型导致的 65 岁以上成人 IPD 发病率在所有六个国家都较高。在美国，65 岁以上人群的 IPD 年发病率（每 10 万人）为 24 例；V116 血清型引起的发病率为 20 例，而 PCV20 血清型引起的发病率为 12 例。结论根据主要国家的IPD监测数据，在2022年65岁以上的成年人中，V116的血清型覆盖率比PCV20高16-33%（英国、法国的数据来自2019年）。V116包括导致大多数IPD的血清型，预计在65岁以上人群中，V116比PCV20能预防更多的IPD病例。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Vaccine 医学-免疫学

CiteScore

8.70

自引率

5.50%

发文量

992

审稿时长

131 days

期刊介绍： Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.